Given the importance of the relationship between the immune system and tumor development in the early stages of disease, along with the relationship between plasma RKIP levels and immune system activation, we set up the first prospective, monocentric case–control pilot study regarding this issue. This evidence concerns the gene PEBP1 and neoplasm.